Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Compulsory License Costs Novartis 5 Percent In Thailand Sales

This article was originally published in PharmAsia News

Executive Summary

Switzerland's Novartis says Thailand's compulsory-licensing system for key drugs will hold its sales growth in the country to only 15 percent, below the 20 percent it had anticipated. The government overrode the Novartis patent earlier this year, allowing an India-made generic version of its cancer drug Femara (letrozole). Novartis avoided a similar CL on its other cancer drug, Gleevec (imatinib), by agreeing to provide some other drugs for free in Thailand. Novartis has a 4.4 percent sales share in Thailand, third behind Pfizer and Sanofi-Aventis. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069015

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel